Assess progress toward standardized, manufacturable microbiome therapies and the regulatory and manufacturing hurdles blocking broader adoption of stool-based treatments.
Key Takeaways
- FDA has approved a single stool-derived therapy for treating C
- FDA has restricted donor-screening services such as Human Microbes, reducing donor access
- Randomized trial found a 15-strain manufactured LBP matched FMT for safety and engraftment